FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a 'monotherapy' treatment for major depressive disorder. The drug was first approved for in 2019 but patients also to be taking an antidepressant at the same time. — Read the rest
The post FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it appeared first on Boing Boing.